JP2015509368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509368A5 JP2015509368A5 JP2014558920A JP2014558920A JP2015509368A5 JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5 JP 2014558920 A JP2014558920 A JP 2014558920A JP 2014558920 A JP2014558920 A JP 2014558920A JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603622P | 2012-02-27 | 2012-02-27 | |
| US61/603,622 | 2012-02-27 | ||
| PCT/US2013/027580 WO2013130381A1 (en) | 2012-02-27 | 2013-02-25 | Cx3cr1-binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509368A JP2015509368A (ja) | 2015-03-30 |
| JP2015509368A5 true JP2015509368A5 (enExample) | 2015-05-07 |
| JP6101715B2 JP6101715B2 (ja) | 2017-03-22 |
Family
ID=47884535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558920A Active JP6101715B2 (ja) | 2012-02-27 | 2013-02-25 | Ｃｘ３ｃｒ１結合ポリペプチド |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9035029B2 (enExample) |
| EP (2) | EP4050027A3 (enExample) |
| JP (1) | JP6101715B2 (enExample) |
| KR (1) | KR102008136B1 (enExample) |
| CN (3) | CN104245735B (enExample) |
| AP (1) | AP2014007791A0 (enExample) |
| AR (1) | AR090158A1 (enExample) |
| AU (1) | AU2013226340B2 (enExample) |
| CA (1) | CA2862182A1 (enExample) |
| CL (1) | CL2014002072A1 (enExample) |
| EA (1) | EA028183B1 (enExample) |
| EC (1) | ECSP14020402A (enExample) |
| GE (1) | GEP201706773B (enExample) |
| IL (3) | IL311502A (enExample) |
| IN (1) | IN2014DN05756A (enExample) |
| MD (1) | MD4548C1 (enExample) |
| MX (1) | MX349192B (enExample) |
| NZ (1) | NZ627260A (enExample) |
| PE (1) | PE20141859A1 (enExample) |
| PH (2) | PH12021553014A1 (enExample) |
| SG (1) | SG11201405283SA (enExample) |
| TN (1) | TN2014000360A1 (enExample) |
| TW (1) | TWI598361B (enExample) |
| UA (1) | UA115781C2 (enExample) |
| UY (1) | UY34644A (enExample) |
| WO (1) | WO2013130381A1 (enExample) |
| ZA (3) | ZA201405021B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
| JP2016534114A (ja) * | 2013-08-21 | 2016-11-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用 |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| KR20180031728A (ko) | 2015-07-23 | 2018-03-28 | 인히브릭스 엘피 | 다가 및 다중특이적 gitr 결합 융합 단백질 |
| WO2017123673A2 (en) | 2016-01-11 | 2017-07-20 | Inhibrx Lp | Multivalent and multispecific ox40-binding fusion proteins |
| CN109071667A (zh) * | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| ES3041302T3 (en) * | 2016-11-29 | 2025-11-11 | Nat Center Neurology & Psychiatry | Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases |
| EP3570883A2 (en) * | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| MX2021001703A (es) | 2018-08-13 | 2021-04-19 | Inhibrx Inc | Polipeptidos de union a ox40 y sus usos. |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| CN110675421B (zh) * | 2019-08-30 | 2022-03-15 | 电子科技大学 | 基于少量标注框的深度图像协同分割方法 |
| WO2021247688A2 (en) * | 2020-06-02 | 2021-12-09 | Children's Medical Center Coproration | Nanobody (vhh) conjugates and uses there of |
| US20240109954A1 (en) * | 2021-02-01 | 2024-04-04 | The General Hospital Corporation | Fc-enhanced antibodies for prevention and treatment of ebola virus infection |
| TW202246334A (zh) * | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
| EP4558520A1 (en) | 2022-07-18 | 2025-05-28 | Ablynx N.V. | Cx3cr1-binding compounds, uses thereof and related methods |
| WO2024135794A1 (ja) * | 2022-12-22 | 2024-06-27 | 株式会社カイオム・バイオサイエンス | 抗ヒトｃｘ３ｃｒ１抗体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| WO2001060406A1 (en) * | 2000-02-18 | 2001-08-23 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20020192212A1 (en) * | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003243532A1 (en) | 2002-06-10 | 2003-12-22 | Metabolex, Inc. | Methods of treating and diagnosing diabetes with cx3cr1 modulators |
| EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| EP1639011B1 (en) | 2003-06-30 | 2008-11-12 | Domantis Limited | Pegylated single domain antibodies (dAb) |
| WO2005103684A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| JP4979388B2 (ja) | 2004-10-29 | 2012-07-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 炎症性疾患治療剤 |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| JP2009504659A (ja) | 2005-08-08 | 2009-02-05 | オンコノン・リミテッド・ライアビリティ・カンパニー | 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法 |
| NZ597168A (en) * | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) * | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| CA2671581A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| CN102112155B (zh) | 2008-06-05 | 2016-08-10 | 埃博灵克斯股份有限公司 | 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽 |
| WO2010070394A1 (en) | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| EP2486056A1 (en) * | 2009-10-09 | 2012-08-15 | Ablynx N.V. | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| US20110085969A1 (en) | 2009-10-09 | 2011-04-14 | Rollo F David | Chelator-targeting ligand conjugates for cardiovascular imaging |
| WO2012078633A2 (en) * | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
| AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
| JP2016534114A (ja) | 2013-08-21 | 2016-11-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用 |
-
2013
- 2013-02-25 AU AU2013226340A patent/AU2013226340B2/en active Active
- 2013-02-25 EP EP22168124.0A patent/EP4050027A3/en active Pending
- 2013-02-25 CN CN201380016996.9A patent/CN104245735B/zh active Active
- 2013-02-25 KR KR1020147023938A patent/KR102008136B1/ko active Active
- 2013-02-25 PH PH1/2021/553014A patent/PH12021553014A1/en unknown
- 2013-02-25 CA CA2862182A patent/CA2862182A1/en not_active Abandoned
- 2013-02-25 EP EP13709641.8A patent/EP2820046B1/en active Active
- 2013-02-25 WO PCT/US2013/027580 patent/WO2013130381A1/en not_active Ceased
- 2013-02-25 NZ NZ627260A patent/NZ627260A/en unknown
- 2013-02-25 UA UAA201410430A patent/UA115781C2/uk unknown
- 2013-02-25 IN IN5756DEN2014 patent/IN2014DN05756A/en unknown
- 2013-02-25 AP AP2014007791A patent/AP2014007791A0/xx unknown
- 2013-02-25 JP JP2014558920A patent/JP6101715B2/ja active Active
- 2013-02-25 US US13/775,307 patent/US9035029B2/en active Active
- 2013-02-25 IL IL311502A patent/IL311502A/en unknown
- 2013-02-25 PH PH1/2014/501912A patent/PH12014501912B1/en unknown
- 2013-02-25 GE GEAP201313583A patent/GEP201706773B/en unknown
- 2013-02-25 MX MX2014009864A patent/MX349192B/es active IP Right Grant
- 2013-02-25 SG SG11201405283SA patent/SG11201405283SA/en unknown
- 2013-02-25 IL IL291571A patent/IL291571B2/en unknown
- 2013-02-25 CN CN201810147778.3A patent/CN108610421B/zh active Active
- 2013-02-25 EA EA201400964A patent/EA028183B1/ru not_active IP Right Cessation
- 2013-02-25 PE PE2014001293A patent/PE20141859A1/es active IP Right Grant
- 2013-02-25 CN CN202210946091.2A patent/CN115925938A/zh active Pending
- 2013-02-25 MD MDA20140104A patent/MD4548C1/ro not_active IP Right Cessation
- 2013-02-26 TW TW102106771A patent/TWI598361B/zh active
- 2013-02-26 AR ARP130100585A patent/AR090158A1/es active IP Right Grant
- 2013-02-27 UY UY0001034644A patent/UY34644A/es unknown
-
2014
- 2014-07-09 ZA ZA2014/05021A patent/ZA201405021B/en unknown
- 2014-08-05 CL CL2014002072A patent/CL2014002072A1/es unknown
- 2014-08-07 IL IL234018A patent/IL234018B2/en unknown
- 2014-08-26 TN TNP2014000360A patent/TN2014000360A1/fr unknown
- 2014-09-25 EC ECIEPI201420402A patent/ECSP14020402A/es unknown
-
2015
- 2015-04-09 US US14/682,131 patent/US9458235B2/en active Active
-
2016
- 2016-08-22 US US15/242,639 patent/US9783612B2/en active Active
-
2017
- 2017-09-29 US US15/720,792 patent/US10385134B2/en active Active
-
2019
- 2019-07-09 US US16/505,773 patent/US11384151B2/en active Active
-
2022
- 2022-06-09 US US17/836,473 patent/US12221487B2/en active Active
-
2023
- 2023-09-19 ZA ZA2023/08846A patent/ZA202308846B/en unknown
- 2023-09-19 ZA ZA2023/08845A patent/ZA202308845B/en unknown